MediPoint: HPV and EBV Tests - Global Analysis and Market Forecasts

  • ID: 4461550
  • Report
  • Region: Global
  • 108 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Abbott
  • Bio-Rad
  • Hologic
  • Qiagen
  • Roche
  • MORE
MediPoint: HPV and EBV Tests - Global Analysis and Market Forecasts

Summary

HPV is a viral infection spread by anal, vaginal, or oral sex or through touching during sexual activity. The breadth of HPV tests focus on women as the aetiological role of the infection is well-established with cervical cancer. Most HPV infections typically resolve within 12 months however infections persisting beyond that increase the chance of precancerous or cancerous lesions. Numerous case studies have linked HPV to cervical carcinoma and HPV 16 accounts for approximately 50% of cervical cancer while HPV 18 for 20% (de Sanjose et al.).

GlobalHuman Papilloma Virus (HPV) and Epstein-barr (EBV) market was estimated at $2.5B in 2017 across the 39 markets covered in this report. By the end of the forecast period in 2024, it is estimated that the market will grow to approximately $3.1B at a Compound Annual Growth Rate (CAGR) of 2.9%.

Key drivers of the HPV and EBV market in the forecast period are:
  • The growing prevalence of HPV related cancers
  • Rise in anogenital warts due to increased sexual activity.
North American HPV and EBV market was estimated at over $635M in 2017for the three markets (US, Canada, and Mexico) covered in this report. By the end of the forecast period in 2024, it is estimated that the market will grow to approximately $0.94Bat a Compound Annual Growth Rate (CAGR) of more than 5.5%.

European HPV and EBV market was estimated at $0.6B in 2017 across the 21 markets (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, Turkey, and the UK) covered in this report. By the end of the forecast period in 2024, it is estimated that the market will grow to approximately over $0.79B at a CAGR of about 4%.

Asia-Pacific (APAC) HPV and EBV market was estimated to be over $1.3B in 2017 across the seven markets (Australia, China, India, Japan, New Zealand, South Korea, and Taiwan) covered in this report. By the end of the forecast period in 2024, it is estimated that the market will grow to approximately $1.8B at a CAGR of over 5%.

South American HPV and EBV market was estimated at $54M in 2017 across the three markets (Argentina, Brazil, and Chile) covered in this report. By the end of the forecast period in 2024, it is estimated that the market will grow to approximately $65.2M at a CAGRof 2.5%.

Middle East and Africa HPV and EBV market was estimated at over $50M in 2017 across the five markets (Egypt, Israel, Saudi Arabia, South Africa, and United Arab Emirates [UAE]) covered in this report. By the end of the forecast period in 2024, it is estimated that the market will grow to approximately $71.3M at a CAGR of about 5%.

The report "MediPoint: HPV and EBV Tests - Global Analysis and Market Forecasts", focuses on the market outlook for HPV and EBV in the global market. This report analyzes and discusses the major drivers and barriers of HPV and EBV testing adoption, and provides an in-depth understanding of the future outlook for this market by geography, with an overall emphasis on the current and future trends in the 39 countries analyzed.

In particular, this report provides the following:
  • In-depth analysis of unmet needs and adoption trends of different HPV and EBV Tests
  • Insightful review of the key industry drivers, opportunities, restraints and challenges.
  • Annualized total HPV and EBV Tests market revenue by segment and market outlooks from 2017-2024.
  • Other key topics covered include strategic competitive assessment, identification of unmet needs, and market dynamics.
Companies mentioned in this report: Abbott, Hologic, Bio-Rad, Qiagen, Roche

Scope
  • Competitive assessment: Currently marketed HPV and EBV Tests and evolving competitive landscape
  • In-depth analysis of unmet needs and adoption trends of different HPV and EBV Tests
  • Insightful review of the key industry drivers, opportunities, restraints and challenges.
  • Annualized total HPV and EBV Tests market revenue by segment and market outlooks from 2017-2024.
  • Other key topics covered include strategic competitive assessment, identification of unmet needs, and market dynamics.
Reasons to buy

The report will enable you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the HPV and EBV Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HPV and EBV Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific HPV and EBV Tests market from 2017-2024.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • Bio-Rad
  • Hologic
  • Qiagen
  • Roche
  • MORE
1 About the Authors

2 Table of Contents
2.1 List of Tables
2.2 List of Figures

3 Executive Summary
3.1 Overview
3.2 Market Dynamics
3.3 Key Players in the Market
3.4 Market Future Outlook

4 Introduction
4.1 Catalyst
4.2 Related Reports
4.3 Upcoming Related Reports

5 Market Outlook
5.1 Procedure Trends
5.2 Revenue Trends
5.3 Company Share Analysis

6 Market Access
6.1 Regulatory Issues
6.1.1 North America
6.1.2 Europe
6.1.3 APAC
6.1.4 South America
6.1.5 Middle East and Africa
6.2 Pricing Trends
6.2.1 North America
6.2.2 Europe
6.2.3 APAC
6.2.4 South America
6.2.5 Middle East and Africa

7 Opportunities, Unmet Needs and Barriers
7.1 Opportunities
7.1.1 Improving screening and treatment of pre-cancer among women
7.1.2 Sensitivity and Specificity
7.1.3 Diagnostic cytology improvements
7.2 Unmet Needs
7.2.1 Point of care testing
7.2.2 Lack of epidemiological studies for underdeveloped regions
7.2.3 Test and testing guidelines for Men
7.3 Barriers
7.3.1 Patient education
7.3.2 Reimbursement
7.3.3 Not approved for primary test

8 Market Insights
8.1 North America
8.1.1 Canada
8.1.2 Mexico
8.1.3 US
8.2 Europe
8.2.1 Denmark, Finland, Norway, and Sweden
8.2.2 Belgium, France, and Netherlands
8.2.3 Germany and Switzerland
8.2.4 UK and Ireland
8.2.5 Italy, Portugal, and Spain
8.2.6 Austria, Czech Republic, Hungary, and Poland
8.2.7 Greece, Russia, and Turkey
8.3 APAC
8.3.1 Australia and New Zealand
8.3.2 China and Taiwan
8.3.3 India
8.3.4 Japan
8.3.5 South Korea
8.4 South America
8.4.1 Brazil
8.4.2 Argentina and Chile
8.5 Middle East and Africa
8.5.1 Israel
8.5.2 South Africa
8.5.3 Egypt, Saudi Arabia, and United Arab Emirates

9 Competitive Assessment
9.1 Overview
9.2 Mergers and Acquisitions
9.3 Abbott
9.3.1 Overview
9.3.2 Portfolio Assessment
9.3.3 Competitive Positioning
9.4 Bio-Rad
9.4.1 Overview
9.4.2 Portfolio Assessment
9.4.3 Competitive Positioning
9.5 Hologic
9.5.1 Overview
9.5.2 Portfolio Assessment
9.5.3 Competitive Positioning
9.6 Qiagen
9.6.1 Overview
9.6.2 Portfolio Assessment
9.6.3 Competitive Positioning
9.7 Roche
9.7.1 Overview
9.7.2 Portfolio Assessment
9.7.3 Competitive Positioning
9.8 Other Players

10 Appendix
10.1 Bibliography
10.2 Abbreviations
10.3 Methodology
10.3.1 Overview
10.3.2 Coverage
10.3.3 Secondary Research
10.3.4 Forecasting Methodology
10.3.5 Primary Research Summary
10.4 About MediPoint
10.5 About
10.6 Contact
10.7 Disclaimer

List of Tables
Table 1: Key Metrics in the Global HPV and EBV Market
Table 2: North America HPV & EBV Tests Volume Forecast, 2015-2024 (in thousands)
Table 3: Europe HPV & EBV Tests Volume Forecast, 2015-2024 (in thousands)
Table 4: APAC HPV & EBV Tests Volume Forecast, 2015-2024 (in thousands)
Table 5: South America HPV & EBV Tests Volume Forecast, 2015-2024 (in thousands)
Table 6: Middle East and Africa HPV & EBV Tests Volume Forecast, 2015-2024 (in thousands)
Table 7: North America HPV & EBV Tests Revenue Forecast ($M), 2015-2024
Table 8: Europe HPV & EBV Tests Revenue Forecast ($M), 2015-2024
Table 9: APAC HPV & EBV Tests Market Revenue Forecast ($M), 2015-2024
Table 10: South America HPV & EBV Tests Revenue Forecast ($M), 2015-2024
Table 11: Middle East and Africa HPV & EBV Tests Revenue Forecast ($M), 2015-2024
Table 12: North America HPV & EBV Tests Company Share Analysis, 2017
Table 13: Europe HPV & EBV Tests Company Share Analysis, 2017
Table 14: APAC HPV & EBV Tests Company Share Analysis, 2017
Table 15: South America HPV & EBV Tests Company Share Analysis, 2017
Table 16: Middle East and Africa HPV & EBV Tests Company Share Analysis, 2017
Table 17: North America HPV & EBV Average Selling Price Forecast ($),2015-2024
Table 18: Europe HPV & EBV Tests Average Selling Price Forecast ($),2015-2024
Table 19: APAC HPV & EBV Tests Average Selling Price Forecast ($),2015-2024
Table 20: South America HPV & EBV Tests Average Selling Price Forecast ($),2015-2024
Table 21: Middle East and Africa HPV & EBV Tests Average Selling Price Forecast ($),2015-2024
Table 22: Mergers and Acquisitions, HPV & EBV Tests
Table 23:Abbott - Key Marketed Products Assessment
Table 24: SWOT Analysis of Abbott in the HPV & EBV Tests, 2017
Table 25: Bio-Rad - Key Marketed Products Assessment
Table 26: SWOT Analysis of Bio-Rad in the HPV & EBV Tests, 2017
Table 27: Hologic - Key Marketed Products Assessment
Table 28: SWOT Analysis of Hologic in the HPV & EBV Tests, 2017
Table 29: Qiagen - Key Marketed Products Assessment
Table 30: SWOT Analysis of Qiagen in the HPV & EBV Tests, 2017
Table 31: Roche - Key Marketed Products Assessment
Table 32: SWOT Analysis of Roche in the HPV & EBV Tests, 2017
Table 33: Summary of Other Players in the HPV & EBV Tests Market, 2017

List of Figures
Figure 1: HPV and EBV Global Sales, by Region, 2017 and 2024
Figure 2: HPV and EBV Sales for North America, by Country, 2017 and 2024
Figure 3: HPV and EBV Sales for Europe, by Country, 2017 and 2024
Figure 4: HPV and EBV Sales for APAC, by Country, 2017 and 2024
Figure 5: HPV and EBV Sales for South America, by Country, 2017 and 2024
Figure 6: HPV and EBV Sales for the Middle East and Africa, by Country, 2017 and 2024
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott
  • Bio-Rad
  • Hologic
  • Qiagen
  • Roche
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll